 CAMBRIDGE, Mass., May 19, 2021 PRNewswire -- Blueprint Medicines Corporation NASDAQ: BPMC today announced the presentation of updated Phase 12 ARROW trial data demonstrating durable clinical benefits of GAVRETO pralsetinib in metastatic RET fusion-positive non-small cell lung cancer NSCLC and other advanced solid tumors. 